Natesto contains testosterone, a Schedule III controlled substance in the Controlled Substances Act. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Exposure of a fetus to androgens may result in varying degrees of virilization. Drug interaction potential with other nasally administered drugs other than oxymetazoline has not been studied. You may report side effects to FDA at FDA-1088. Call your doctor for medical advice about side effects. These are not all the possible side effects of Natesto. Natesto is for use in your nose (intranasally) only.
